BG & TMZ Therapy of Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 22, 2011

Primary Completion Date

December 7, 2020

Study Completion Date

September 26, 2022

Conditions

Glioblastoma Multiforme

Interventions

BIOLOGICAL

MGMTP140K-encoding retroviral vector

DRUG

O6-benzylguanine

DRUG

temozolomide

OTHER

laboratory biomarker analysis

PROCEDURE

autologous hematopoietic stem cell transplantation

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

RADIATION

radiation therapy

Trial Locations (1)

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Stanton Gerson MD

OTHER

NCT01269424 - BG & TMZ Therapy of Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter